Clinical Trial Update: Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating EKB-569 in advanced non-small cell lung cancer has completed enrollment and the trial status is reported as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EKB-569 (EKB-569)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Non-Small-Cell Lung Carcinoma, Carcinoma, Non-Small Cell Lung | Phase 2 | Status: COMPLETED